| Pierce, Kristen |
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge |
|
|
| Recruiting | 2 | 54 | US | JNJ-64281802 (sentinel high dose), JNJ-64281802 (remaining high dose), JNJ-64281802 (medium/low dose), JNJ-64281802 (daily dosing regimen X), JNJ-64281802 (weekly dosing regimen Y1), JNJ-64281802 (weekly dosing regimen Z2), Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH) | Dengue | 05/23 | 08/24 | | |
| Durbin, Anna |
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge |
|
|
| Recruiting | 2 | 54 | US | JNJ-64281802 (sentinel high dose), JNJ-64281802 (remaining high dose), JNJ-64281802 (medium/low dose), JNJ-64281802 (daily dosing regimen X), JNJ-64281802 (weekly dosing regimen Y1), JNJ-64281802 (weekly dosing regimen Z2), Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH) | Dengue | 05/23 | 08/24 | | |
NCT05123222: Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) |
|
|
| Recruiting | 1 | 56 | US | ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Zika Virus | 07/24 | 08/24 | | |
NCT06805487: Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge |
|
|
| Recruiting | 1 | 26 | US | TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184 | National Institute of Allergy and Infectious Diseases (NIAID), Johns Hopkins Bloomberg School of Public Health | Zika Virus | 09/25 | 09/25 | | |
| Lutton, Patricia |
NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge |
|
|
| Recruiting | 2 | 54 | US | JNJ-64281802 (sentinel high dose), JNJ-64281802 (remaining high dose), JNJ-64281802 (medium/low dose), JNJ-64281802 (daily dosing regimen X), JNJ-64281802 (weekly dosing regimen Y1), JNJ-64281802 (weekly dosing regimen Z2), Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH) | Dengue | 05/23 | 08/24 | | |
| Recruiting | 2 | 84 | US | AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo | AbViro LLC | DENV-3 Controlled Human Infection Model | 10/25 | 10/25 | | |
